Bank of America
MIRM icon

Bank of America’s Mirum Pharmaceuticals MIRM Stock Holding History

Bank of America’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.8M Sell
561,724
-160,453
-22% -$16.1M ﹤0.01% 1489
2026
Q1 		$66.7M Buy
722,177
+8,725
+1% +$821K ﹤0.01% 1404
2025
Q4 		$56.4M Buy
713,452
+322,978
+83% +$23.2M ﹤0.01% 1471
2025
Q3 		$28.6M Buy
390,474
+1,204
+0.3% +$76.5K ﹤0.01% 2248
2025
Q2 		$19.8M Buy
389,270
+10,648
+3% +$474K ﹤0.01% 2560
2025
Q1 		$17.1M Sell
378,622
-64,005
-14% -$3.02M ﹤0.01% 2616
2024
Q4 		$18.3M Sell
442,627
-23,582
-5% -$983K ﹤0.01% 2392
2024
Q3 		$18.2M Buy
466,209
+134,108
+40% +$5.35M ﹤0.01% 2488
2024
Q2 		$11.4M Buy
332,101
+19,488
+6% +$511K ﹤0.01% 2824
2024
Q1 		$7.85M Buy
312,613
+161,789
+107% +$4.45M ﹤0.01% 3213
2023
Q4 		$4.45M Buy
150,824
+28,175
+23% +$853K ﹤0.01% 3645
2023
Q3 		$3.88M Buy
122,649
+37,914
+45% +$1.04M ﹤0.01% 3640
2023
Q2 		$2.19M Sell
84,735
-21,128
-20% -$562K ﹤0.01% 4148
2023
Q1 		$2.54M Sell
105,863
-81,518
-44% -$1.86M ﹤0.01% 4137
2022
Q4 		$3.65M Buy
187,381
+133,139
+245% +$2.63M ﹤0.01% 3697
2022
Q3 		$1.14M Buy
54,242
+44,626
+464% +$1.07M ﹤0.01% 4780
2022
Q2 		$187K Buy
9,616
+4,002
+71% +$94.4K ﹤0.01% 6141
2022
Q1 		$124K Sell
5,614
-1,092
-16% -$22.3K ﹤0.01% 6745
2021
Q4 		$107K Buy
6,706
+3,391
+102% +$52.8K ﹤0.01% 6852
2021
Q3 		$66K Buy
3,315
+596
+22% +$9.69K ﹤0.01% 6918
2021
Q2 		$47K Sell
2,719
-4,152
-60% -$74.4K ﹤0.01% 6866
2021
Q1 		$136K Buy
6,871
+3,944
+135% +$75.5K ﹤0.01% 6265
2020
Q4 		$52K Buy
2,927
+1,131
+63% +$22.2K ﹤0.01% 6313
2020
Q3 		$35K Sell
1,796
-989
-36% -$21.2K ﹤0.01% 6145
2020
Q2 		$55K Sell
2,785
-1,244
-31% -$20.8K ﹤0.01% 5946
2020
Q1 		$57K Sell
4,029
-1,356
-25% -$22.3K ﹤0.01% 5818
2019
Q4 		$132K Buy
5,385
+284
+6% +$3.03K ﹤0.01% 5860
2019
Q3 		$51K Buy
+5,101
New +$62.6K ﹤0.01% 6320

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America's MIRM Position: Q2 2026 in Review

Bank of America reduced its Mirum Pharmaceuticals (MIRM) stake by 22% in Q2 2026, selling an estimated $16.1M and leaving 561,724 shares worth $65.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Bank of America first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. The position peaked at $66.7M in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Bank of America held 561,724 shares of Mirum Pharmaceuticals worth $65.8M as of Q2 2026.
  • Bank of America sold 160,453 Mirum Pharmaceuticals shares in Q2 2026, an estimated $16.1M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1489 holding.
  • Bank of America first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Bank of America's Mirum Pharmaceuticals position peaked at $66.7M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.